With over 15 years experience in designing, collecting and analysing preclinical multi-modal neuroimaging experiments for the pharmaceutical industry, we understand what is important to our clients: increasing confidence in preclinical data, improving success rates in clinical trials and reducing time-to-market.
Preclinical neuroimaging is the use of imaging technology to study the structure and function of the brain in animal models. It is a powerful tool for understanding the neuropathology of diseases, developing novel therapeutics and understanding physiology. L&M Data Science counts with a network of neuroimaging experts that can provide you with a range of services to help you with your drug discovery programme:
Data Interpretation: Our experts can analyze preclinical neuroimaging data to identify patterns of brain activity and pathology. They can help to assess the efficacy of treatments and to identify areas of the brain that may be affected by a disorder. This can be invaluable for understanding the mechanisms of disease and developing novel treatments.
Experimental Design: We can help you design your preclinical neuroimaging experiments to meet your specific research goals. We can review existing studies and discuss potential modifications that might improve the experimental design. Our experts can also provide advice on the most appropriate imaging technology for a given study.
Contact us today to learn more about how we can help you achieve your development goals.
We offer neuroimaging and corroborative techniques mainly in rodents, be it naïve or a number of validated CNS disorder models.
In order to offer our clients speed and scalability, we are building a network of state-of-the-art facilities with access to the latest in the following techniques:
MRI, ranging from 7 to 11T
EEG, with capability of micro array electrodes (32 channels in freely moving subjects)
Concomitant EEG and fMRI (coming soon)
In addition, we offer neuroPhINDr, a set of highly optimised and standardised acquisition and analysis protocols, providing our quickest and most comprehensive tool to fingerprint your new compound. With neuroPhINDr, we can classify your drug, using AI-powered algorithms, saving you time and increasing your confidence moving into early clinical trials. Read more.
At L&M, we are constantly rethinking and optimising our analysis pipelines. We employ the latest in data processing, ranging from fully validated methods to state-of-the-art machine learning. We use highly scalable cloud computing resources, making sure we always deliver your results as quickly as possible, no matter the size of your dataset.
Using neuroPhINDr, our AI-powered drug classification algorithm, we can determine the therapeutical class that best matches your new compound, among a number of CNS applications (eg, antidepressants, anti-epileptics, antipsychotics, etc). neuroPhINDr gives you confidence your compound is hitting the correct target, but can also indicate new applications for your therapy. Ask us how.
At L&M our main mission is to deliver results with real translational value to our clients in the pharmaceutical industry. Making sense of complex data is our passion.
We are experts in developing powerful, reliable and highly automated image analysis tools. Harnessing the power of cloud computing, we can create innovative solutions for your needs, no matter how large or complex your data is.
Get in touch to see how we can help.